Thursday, March 23, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This activity is intended for oncologists, pulmonologists, and pharmacists.
The goal of this activity is to improve clinicians' ability to manage patients with extensive-stage (ES) small cell lung cancer (SCLC).
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Associate Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina
None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-21-468-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 8/30/2021
Valid for credit through: 8/30/2022
processing....
AID = autoimmune disease
AUC = area under curve
BSC = best supportive care
CAV = cyclophosphamide, doxorubicin, vincristine
CbP = Carboplatin/pemetrexed
CNS = central nervous system
CT = computed tomography
CTCAE = Common Terminology Criteria for Adverse Events
CTFI = chemotherapy-free interval
CXR = chest x-ray
DOR = duration of response
D+EP = durvalumab plus platinum-etoposide
ECOG PS = Eastern Cooperative Oncology Group performance status
EP = cisplatin + etoposide
ESA = erythropoiesis-stimulating agent
ES-SCLC = extensive-stage small cell lung cancer
FDG = fluoro-2-deoxy-D-glucose
FN = febrile neutropenia
G-CSF = granulocyte-colony stimulating factor
ICI = immune checkpoint inhibitor
irAE = immune-related adverse event
IV = intravenous
LS-SCLC = limited-stage small cell lung cancer
MRI = magnetic resonance imaging
NR = not reported
NSAID = nonsteroidal anti-inflammatory drug
NYR = not yet reached
N/A = not available
ORR = overall response rate
OS = overall survival
PD = progressive disease
PD-1 = programmed cell death protein-1
PD-L1 = programmed death-ligand 1
PET = positron emission tomography
PFS = progression-free survival
PR = partial response
PRA = polymyalgia rheumatica
PRO = patient-reported outcome
QoL = quality of life
RA = rheumatoid arthritis
RBC = red blood cell
RR = relative risk
SLE = systemic lupus erythematosus
SCLC = small cell lung cancer
SN = severe neutropenia
TRAE = treatment-related adverse event
TTCD = time to confirmed deterioration
TTP = time to progression
| « Return to: Clinical Cases in Extensive-Stage SCLC |
